NR1H4 and diabetes mellitus: The efficacy of synthetic FXR agonists as potential therapy for type 2 diabetes mellitus has been proven in an already mentioned phase II clinical trial conducted by Mudaliar et al. (2013) showing that administration of OCA to patients with both type 2 diabetes mellitus and NAFLD for 6 weeks was well-tolerated, improving insulin sensitivity, and reducing markers of liver inflammation and fibrosis.